Key Insights from CB Capital’s Report: The Company previously entered into an engagement agreement with CB Capital Partners in which CB Capital Partners will serve as financial advisor in connection ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company ...
The Company previously entered into an engagement agreement with CB Capital Partners in which CB Capital Partners will serve as financial advisor in connection with the preparation of an Initiatio ...
EMERYVILLE, Calif., March 05, 2025--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback